title: Posttransplantation maintenance therapy and optimal frontline therapy in myeloma.
abstract: One of the major efforts to improve the results of intensive therapy and autologous stem cell transplantation (ASCT) in multiple myeloma involves the integration of novel agents into the transplantation sequence. This can include their administration before, during, and after the transplantation procedure. Several phase 2 and 3 studies have evaluated the use of novel agents as part of induction therapy before transplantation to produce higher response rates and progression-free survival (PFS). Similarly, posttransplantation maintenance-or consolidation-with these agents consistently improves PFS. Survival benefits have been more difficult to demonstrate, although one trial using bortezomib before and after transplantation and a second using lenalidomide as maintenance have shown significantly longer survival times. This article reviews the different regimens used with ASCT, with an emphasis on randomized trials.
authors.affiliation: Princess Margaret Hospital, Toronto, ON, Canada. donna.reece@uhn.on.ca
authors.forename: Donna E
authors.initials: DE
authors.lastname: Reece
mesh_terms: D006801:Humans; D060828:Induction Chemotherapy; D060046:Maintenance Chemotherapy / Q000379:methods*; D009101:Multiple Myeloma / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D033581:Stem Cell Transplantation